WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H598249
CAS#: 91161-71-6 (free base)
Description: Terbinafine is a synthetic antifungal agent inhibiting fungal squalene epoxidase; TDT-067 is terbinafine in Transferome.
Hodoodo Cat#: H598249
Name: Terbinafine free base
CAS#: 91161-71-6 (free base)
Chemical Formula: C21H25N
Exact Mass: 291.20
Molecular Weight: 291.430
Elemental Analysis: C, 86.55; H, 8.65; N, 4.81
Related CAS #: 91161-71-6 (free base) 78628-80-5 (HCl) 335276-86-3 (lactate)
Synonym: Terbinafine; SF 86-327; SF-86-327; SF86-327; Lamasil; Lamisil AT;
IUPAC/Chemical Name: (E)-N,6,6-trimethyl-N-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine
InChi Key: DOMXUEMWDBAQBQ-WEVVVXLNSA-N
InChi Code: InChI=1S/C21H25N/c1-21(2,3)15-8-5-9-16-22(4)17-19-13-10-12-18-11-6-7-14-20(18)19/h5-7,9-14H,16-17H2,1-4H3/b9-5+
SMILES Code: CC(C)(C)C#C/C=C/CN(C)CC1=C2C=CC=CC2=CC=C1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 291.43 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Saarikoski T, Saari TI, Hagelberg NM, Backman JT, Neuvonen PJ, Scheinin M, Olkkola KT, Laine K. Effects of terbinafine and itraconazole on the pharmacokinetics of orally administered tramadol. Eur J Clin Pharmacol. 2015 Mar;71(3):321-7. doi: 10.1007/s00228-014-1799-2. Epub 2015 Jan 6. PubMed PMID: 25560051.
2: Yadav P, Singal A, Pandhi D, Das S. Comparative efficacy of continuous and pulse dose terbinafine regimes in toenail dermatophytosis: A randomized double-blind trial. Indian J Dermatol Venereol Leprol. 2015 Jul-Aug;81(4):363-9. doi: 10.4103/0378-6323.158634. PubMed PMID: 26087080.
3: Bebawi E, Jouni SS, Tessier AA, Frenette AJ, Brindamour D, Doré M. A metoprolol-terbinafine combination induced bradycardia. Eur J Drug Metab Pharmacokinet. 2015 Sep;40(3):295-9. doi: 10.1007/s13318-014-0205-x. Epub 2014 Jun 4. PubMed PMID: 24894748.
4: Gupta AK, Paquet M, Simpson F, Tavakkol A. Terbinafine in the treatment of dermatophyte toenail onychomycosis: a meta-analysis of efficacy for continuous and intermittent regimens. J Eur Acad Dermatol Venereol. 2013 Mar;27(3):267-72. doi: 10.1111/j.1468-3083.2012.04584.x. Epub 2012 May 28. Review. PubMed PMID: 22632057.
5: Yan J, Wang X, Chen S. Systematic review of severe acute liver injury caused by terbinafine. Int J Clin Pharm. 2014 Aug;36(4):679-83. doi: 10.1007/s11096-014-9969-y. Epub 2014 Jul 2. Review. PubMed PMID: 24986266.
6: George A, Bhatia A, Kanish B, Williams A. Terbinafine induced pityriasis rosea-like eruption. Indian J Pharmacol. 2015 Nov-Dec;47(6):680-1. doi: 10.4103/0253-7613.169574. PubMed PMID: 26729964; PubMed Central PMCID: PMC4689026.
7: Alipour M, Mozafari NA. Terbinafine susceptibility and genotypic heterogeneity in clinical isolates of Trichophyton mentagrophytes by random amplified polymorphic DNA (RAPD). J Mycol Med. 2015 Mar;25(1):e1-9. doi: 10.1016/j.mycmed.2014.09.001. Epub 2015 Jan 30. PubMed PMID: 25649232.
8: Dürrbeck A, Nenoff P. [Terbinafine : Relevant drug interactions and their management]. Hautarzt. 2016 Sep;67(9):718-23. doi: 10.1007/s00105-016-3853-8. Review. German. PubMed PMID: 27474731.
9: Li RY, Wang AP, Xu JH, Xi LY, Fu MH, Zhu M, Xu ML, Li XQ, Lai W, Liu WD, Lu XY, Gong ZQ. Efficacy and safety of 1 % terbinafine film-forming solution in Chinese patients with tinea pedis: a randomized, double-blind, placebo-controlled, multicenter, parallel-group study. Clin Drug Investig. 2014 Mar;34(3):223-30. doi: 10.1007/s40261-014-0171-8. PubMed PMID: 24477462; PubMed Central PMCID: PMC3926983.
10: Dolton MJ, Perera V, Pont LG, McLachlan AJ. Terbinafine in combination with other antifungal agents for treatment of resistant or refractory mycoses: investigating optimal dosing regimens using a physiologically based pharmacokinetic model. Antimicrob Agents Chemother. 2014;58(1):48-54. doi: 10.1128/AAC.02006-13. Epub 2013 Oct 14. PubMed PMID: 24126579; PubMed Central PMCID: PMC3910715.
11: Mayser P. [Terbinafine : Drug-induced lupus erythematodes and triggering of psoriatic skin lesions]. Hautarzt. 2016 Sep;67(9):724-31. doi: 10.1007/s00105-016-3844-9. Review. German. PubMed PMID: 27455869.
12: Thapa RK, Han SD, Park HG, Son M, Jun JH, Kim JO. DA 5505: a novel topical formulation of terbinafine that enhances skin penetration and retention. Chem Pharm Bull (Tokyo). 2015;63(7):525-30. doi: 10.1248/cpb.c15-00108. Epub 2015 May 9. PubMed PMID: 25958812.
13: Ma Y, Chen X, Guan S. Terbinafine: novel formulations that potentiate antifungal activities. Drugs Today (Barc). 2015 Mar;51(3):197-208. doi: 10.1358/dot.2015.51.3.2295906. Review. PubMed PMID: 25876563.
14: Erdal MS, Peköz AY, Aksu B, Araman A. Impacts of chemical enhancers on skin permeation and deposition of terbinafine. Pharm Dev Technol. 2014 Aug;19(5):565-70. doi: 10.3109/10837450.2013.813538. Epub 2013 Jul 10. PubMed PMID: 23841559.
15: Ranawaka RR, Nagahawatte A, Gunasekara TA. Fusarium onychomycosis: prevalence, clinical presentations, response to itraconazole and terbinafine pulse therapy, and 1-year follow-up in nine cases. Int J Dermatol. 2015 Nov;54(11):1275-82. doi: 10.1111/ijd.12906. Epub 2015 Jul 29. PubMed PMID: 26223159.
16: Shemer A, Sakka N, Baran R, Scher R, Amichai B, Norman L, Farhi R, Magun R, Brazilai A, Daniel R. Clinical comparison and complete cure rates of Terbinafine efficacy in affected onychomycotic toenails. J Eur Acad Dermatol Venereol. 2015 Mar;29(3):521-6. doi: 10.1111/jdv.12609. Epub 2014 Jul 30. PubMed PMID: 25079781.
17: Täuber A, Müller-Goymann CC. Comparison of the antifungal efficacy of terbinafine hydrochloride and ciclopirox olamine containing formulations against the dermatophyte Trichophyton rubrum in an infected nail plate model. Mol Pharm. 2014 Jul 7;11(7):1991-6. doi: 10.1021/mp400711q. Epub 2014 Feb 12. PubMed PMID: 24490976.
18: Hu Y, Huang X, Lu S, Hamblin MR, Mylonakis E, Zhang J, Xi L. Photodynamic therapy combined with terbinafine against chromoblastomycosis and the effect of PDT on Fonsecaea monophora in vitro. Mycopathologia. 2015 Feb;179(1-2):103-9. doi: 10.1007/s11046-014-9828-3. Epub 2014 Nov 1. PubMed PMID: 25366276; PubMed Central PMCID: PMC4323679.
19: Çelebi N, Ermiş S, Özkan S. Development of topical hydrogels of terbinafine hydrochloride and evaluation of their antifungal activity. Drug Dev Ind Pharm. 2015 Apr;41(4):631-9. doi: 10.3109/03639045.2014.891129. Epub 2014 Feb 27. PubMed PMID: 24576265.
20: Ahn TS, Lee JP, Kim J, Oh SY, Chun MK, Choi HK. Effect of pressure sensitive adhesive and vehicles on permeation of terbinafine across porcine hoof membrane. Arch Pharm Res. 2013 Nov;36(11):1403-9. doi: 10.1007/s12272-013-0191-6. Epub 2013 Jul 1. PubMed PMID: 23812776.
